Assessing the importance of domestic vaccine manufacturing centers: An overview of immunization programs, vaccine manufacture, and distribution

Vista sencilla de ítem
dc.contributor.authorRey-Jurado, Emma
dc.contributor.authorTapia, Felipe
dc.contributor.authorMuñoz-Durango, Natalia
dc.contributor.authorLay, Margarita K.
dc.contributor.authorCarreño, Leandro J.
dc.contributor.authorRiedel, Claudia A.
dc.contributor.authorBueno, Susan M.
dc.contributor.authorGenzel, Yvonne
dc.contributor.authorKalergis, Alexis M.
dc.date.accessioned2022-08-31T13:22:55Z
dc.date.available2022-08-31T13:22:55Z
dc.date.issued2018-01
dc.descriptionIndexación Scopuses
dc.description.abstractVaccines have significantly reduced the detrimental effects of numerous human infectious diseases worldwide, helped to reduce drastically child mortality rates and even achieved eradication of major pathogens, such as smallpox. These achievements have been possible due to a dedicated effort for vaccine research and development, as well as an effective transfer of these vaccines to public health care systems globally. Either public or private institutions have committed to developing and manufacturing vaccines for local or international population supply. However, current vaccine manufacturers worldwide might not be able to guarantee sufficient vaccine supplies for all nations when epidemics or pandemics events could take place. Currently, different countries produce their own vaccine supplies under Good Manufacturing Practices, which include the USA, Canada, China, India, some nations in Europe and South America, such as Germany, the Netherlands, Italy, France, Argentina, and Brazil, respectively. Here, we discuss some of the vaccine programs and manufacturing capacities, comparing the current models of vaccine management between industrialized and developing countries. Because local vaccine production undoubtedly provides significant benefits for the respective population, the manufacture capacity of these prophylactic products should be included in every country as a matter of national safety. © 2018 Rey-Jurado, Tapia, Muñoz-Durango, Lay, Carreño, Riedel, Bueno, Genzel and Kalergis.es
dc.description.urihttps://www.frontiersin.org/articles/10.3389/fimmu.2018.00026/full
dc.identifier.citationFrontiers in Immunology Volume 9, Issue JAN18 January 2018 Article number 26es
dc.identifier.doi10.3389/fimmu.2018.00026
dc.identifier.issn16643224
dc.identifier.urihttps://repositorio.unab.cl/xmlui/handle/ria/23683
dc.language.isoenes
dc.publisherFrontiers Media S.A.es
dc.rights.licenseCC BY 4.0
dc.subjectTyphoid Feveres
dc.subjectSalmonella Enterica Serovar Typhies
dc.subjectGood manufacturing practiceses
dc.subjectImmunization programses
dc.subjectVaccine distributiones
dc.titleAssessing the importance of domestic vaccine manufacturing centers: An overview of immunization programs, vaccine manufacture, and distributiones
dc.typeArtículoes
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Rey-Jurado_E_Assessing_2018.pdf
Tamaño:
1.34 MB
Formato:
Adobe Portable Document Format
Descripción:
TEXTO COMPLETO EN INGLÉS
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
FM - Artículos de Revista